pyrazinamide and moxifloxacin

pyrazinamide has been researched along with moxifloxacin in 87 studies

Research

Studies (87)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (16.09)	29.6817
2010's	57 (65.52)	24.3611
2020's	16 (18.39)	2.80

Authors

Authors	Studies
Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J	1
Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ	1
Barry, CE; Dartois, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS	1
Cokolova, GB; Elistratova, NA; Lazareva, IaV; Mozhokina, GN; Perel'man, MI; Strekchev, AIu	1
Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J	1
Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K	1
Andries, K; Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Chau, CH; Wong, HY; Yew, WW	1
Kubendiran, G; Mitchison, DA; Paramasivan, CN; Sulochana, S	1
Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M	1
Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW	1
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN	1
Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M	1
Bishai, WR; Cezar, MC; Chaisson, RE; Chaudhary, MA; Conde, MB; De Souza, GR; Efron, A; Graça, NP; Kritski, AL; Loredo, C; Ram, M	1
Gumbo, T	1
Oliver, GF; Wong, KK	1
Andries, K; Gevers, T; Lounis, N	1
Hutson, S	1
Butcher, PD; Coleman, D; Cosgrove, CA; Delgado, R; Feasey, NA; Harrison, T; Mitchison, DA; Pond, M; Solomon, AW	1
DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM	1
Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK	1
Colucci, G; Silzle, T; Solenthaler, M	1
Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D	1
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M	1
Roehr, B	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H	1
Kmietowicz, Z	1
Ahmad, Z; Grosset, JH; Minkowski, A; Nuermberger, EL; Peloquin, CA; Tyagi, S	1
Dawson, R; Diacon, A	1
Chang, KC; Dheda, K	1
Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S	1
Blyth, CC; Colby, S; Fagan, JM; Francis, JR; Waring, J	1
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA	1
Diao, C; Liang, L; Liu, X; Wang, L; Xu, Y; Zhang, J; Zhang, S	1
Bagcchi, S	1
Crook, AM; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Murray, SR; Nunn, AJ; Pappas, F; Phillips, PP	1
Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A	1
de Droogh, E; Groenen, G; Mathys, V; Soetaert, K; van de Vyvere, M	1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K	1
Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP	1
Adelakun, A; Bhatnagar, V; Chen, Q; Emadi, A; Farshidpour, M; Holtzman, N; Kendall, T; Stevenson, B	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Migliori, GB; Sotgiu, G	1
Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS	1
Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM	1
Blackmore, T; McNaughton, A; McNaughton, H	1
Karak, A; Mukhopadhay, S; Paul, R; Santra, G	1
Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A	1
Fang, X; Li, Q; Ou, X; Pang, Y; Song, Y; Wang, S; Wang, Y; Xia, H; Zhang, Z; Zhao, B; Zhao, Y; Zheng, Y; Zhou, Y	1
Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ	1
Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS	1
Mendel, C; Murray, S; Spigelman, M	1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S	1
Chen, YH; Huang, CH; Kuo, CY; Lu, PL; Wang, WH	1
Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T	1
Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC	1
Cavallaro, A; Das, SC; Doyle, C; Eedara, BB; Rangnekar, B	1
Cavallaro, A; Das, SC; Doyle, C; Eedara, BB; Rangnekar, B; Sinha, S	1
Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A	1
Carrera-Pineda, R; Garcia-Luna, RC; Soto-Cabrera, E; Villamil-Osorio, LV	1
Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM	1
Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S	1
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH	1
Das, SC; Eedara, BB; Momin, MAM; Rangnekar, B; Sinha, S	1
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J	1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E	1
Furin, J; McKenna, L	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS	1
Ahmad, N; Atif, M; Ghafoor, A; Iqbal, Q; Khan, S; Latif, A; Saleem, F; Wahid, A	1
Basdeo, SA; Cahill, C; Cox, DJ; Gogan, KM; Gordon, SV; Keane, J; O'Connell, F; O'Sullivan, J; Phelan, JJ	1
Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C	1
Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD	1
Arodola-Oladoyinbo, O; Chirehwa, M; Denti, P; Gengiah, TN; Kawuma, AN; Naidoo, A; Naidoo, K; Padayatchi, N; Perumal, R	1
Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM	1
Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M	1
Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y	1
Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E	1
Aalhoul, F; Cotton, F; Fage, D	1
Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S	1

Reviews

6 review(s) available for pyrazinamide and moxifloxacin

Article	Year
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis	2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2013
Managing multidrug-resistant tuberculosis in children: review of recent developments. Current opinion in infectious diseases, 2014, Volume: 27, Issue:3 Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2014
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
[Treatment of tuberculosis: what is new?] Innere Medizin (Heidelberg, Germany), 2023, Volume: 64, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023

Trials

15 trial(s) available for pyrazinamide and moxifloxacin

Article	Year
[Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2004, Volume: 49, Issue:6 Topics: Adolescent; Adult; Animals; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Mice; Middle Aged; Moxifloxacin; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2004
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum	2008
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Kaplan-Meier Estimate; Logistic Models; Male; Moxifloxacin; Multivariate Analysis; Pyrazinamide; Quinolines; Rifampin; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2009
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846 Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult	2012
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, Sep-09, Volume: 15 Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:8 Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Area Under Curve; Cycloserine; Drug Monitoring; Fluoroquinolones; Healthy Volunteers; Humans; Kanamycin; Levofloxacin; Male; Moxifloxacin; Prothionamide; Pyrazinamide; Streptomycin; Young Adult	2015
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2016
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1 Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary	2017
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda	2019
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. The Lancet. Microbe, 2020, Volume: 1, Issue:2 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2020
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. BMC infectious diseases, 2023, May-08, Volume: 23, Issue:1 Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis	2023

Other Studies

66 other study(ies) available for pyrazinamide and moxifloxacin

Article	Year
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; Lung; Mice; Organ Size; Pyrazinamide; Quinolines; Spleen; Survival Analysis; Tuberculosis, Pulmonary	2007
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen	2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary	2010
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin	2010
A whole blood bactericidal assay for tuberculosis. The Journal of infectious diseases, 2001, Apr-15, Volume: 183, Issue:8 Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin	2001
[Cervical spondylodiscitis: one pathogen may hide another]. Medecine et maladies infectieuses, 2006, Volume: 36, Issue:1 Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal	2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2006
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:11 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ethionamide; Fluoroquinolones; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Pyrazinamide; Quinolines; Rifampin; Spleen; Survival Analysis; Tuberculosis	2006
Moxifloxacin-induced arthropathy. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2007, Volume: 11, Issue:1 Topics: Aged, 80 and over; Antitubercular Agents; Arthritis; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2007
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:6 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Time Factors	2006
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS medicine, 2007, Volume: 4, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis	2007
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary	2008
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American journal of respiratory and critical care medicine, 2008, Nov-01, Volume: 178, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis	2008
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
Simultaneous scrofuloderma and intracranial tuberculomas: a rare presentation of systemic tuberculosis. The Australasian journal of dermatology, 2010, Volume: 51, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Brain; Diagnosis, Differential; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Lichenoid Eruptions; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Cutaneous	2010
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2010
Half-century-old TB drugs get a facelift in new cocktails. Nature medicine, 2010, Volume: 16, Issue:12 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2010
Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:3 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2011
Torticollis in mice intravenously infected with Mycobacterium tuberculosis. Journal of the American Association for Laboratory Animal Science : JAALAS, 2011, Volume: 50, Issue:2 Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Ear, Middle; Female; Fluoroquinolones; Injections, Intravenous; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Otitis Media; Pyrazinamide; Quinolines; Rifampin; Torticollis; Tuberculosis	2011
Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 10 Topics: Antitubercular Agents; Aza Compounds; Biopsy; Brain; Cerebrospinal Fluid; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Histocytochemistry; Humans; Isoniazid; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Multidrug-Resistant; Young Adult	2011
Pyrazinamide-induced sideroblastic anemia. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: 5-Aminolevulinate Synthetase; alpha-Thalassemia; Anemia, Sideroblastic; Antitubercular Agents; Aza Compounds; Bone Marrow; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hemolysis; Humans; Isoniazid; Middle Aged; Moxifloxacin; Peritonitis, Tuberculous; Pyrazinamide; Pyridoxine; Quinolines; Rifampin	2012
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug Administration Schedule; Female; Fluoroquinolones; Granuloma; Humans; Isoniazid; Lung; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rabbits; Rifampin; Tissue Extracts; Tuberculosis, Pulmonary	2012
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2012
Trial tests new combination of drugs to treat tuberculosis. BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States	2012
New drug combination for TB is tested in unique trial. BMJ (Clinical research ed.), 2012, Jul-25, Volume: 345 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2012
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. American journal of respiratory and critical care medicine, 2013, Jul-01, Volume: 188, Issue:1 Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Levofloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2013
Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis. American journal of respiratory and critical care medicine, 2013, Jul-01, Volume: 188, Issue:1 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Female; Fluoroquinolones; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Tuberculosis	2013
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2 Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2014
Multidrug-resistant tuberculosis in Western Australia, 1998-2012. The Medical journal of Australia, 2014, Apr-07, Volume: 200, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Child; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hospitalization; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Retrospective Studies; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Western Australia; Young Adult	2014
LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2014, Volume: 97 Topics: Animals; Chromatography, Liquid; Drug Interactions; Fluoroquinolones; Limit of Detection; Metronidazole; Moxifloxacin; Nitroimidazoles; Plasma; Pyrazinamide; Rats; Tandem Mass Spectrometry	2014
Novel drug combination for tuberculosis to be tested across 50 sites. BMJ (Clinical research ed.), 2014, May-27, Volume: 348 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2014
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10 Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Fluoroquinolones; Genotype; Humans; Isoniazid; Male; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Phenotype; Pyrazinamide; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Pulmonary	2014
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis	2015
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. Archives of Iranian medicine, 2015, Volume: 18, Issue:1 Topics: Adult; Antitubercular Agents; Dasatinib; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Moxifloxacin; Peritonitis, Tuberculous; Protein Kinase Inhibitors; Pyrazinamide; Pyrimidines; Thiazoles	2015
New effective antituberculosis regimens. Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand. The European respiratory journal, 2016, Volume: 48, Issue:4 Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary	2016
Gitelman-like Syndrome with Kanamycin Toxicity. The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5 Topics: Adult; Alkalosis; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Hypokalemia; Kanamycin; Moxifloxacin; Muscle Cramp; Potassium; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2016
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 56 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization	2017
Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:2 Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Prevalence; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2017
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of pharmaceutical and biomedical analysis, 2017, Feb-20, Volume: 135 Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary	2017
Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2018, Volume: 51, Issue:1 Topics: Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Streptomycin; Taiwan	2018
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. Bioinformatics (Oxford, England), 2018, 05-15, Volume: 34, Issue:10 Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant	2018
Antituberculosis Treatment in a Patient with Celiac Disease. Archivos de bronconeumologia, 2018, Volume: 54, Issue:6 Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2018
The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders. International journal of pharmaceutics, 2018, May-05, Volume: 542, Issue:1-2 Topics: 1,2-Dipalmitoylphosphatidylcholine; Aerosols; Antitubercular Agents; Chemistry, Pharmaceutical; Desiccation; Excipients; Fluoroquinolones; Leucine; Moxifloxacin; Particle Size; Powders; Pyrazinamide	2018
Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jun-15, Volume: 118 Topics: Aerosols; Antitubercular Agents; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Drug Combinations; Drug Stability; Fluoroquinolones; Humans; Moxifloxacin; Powders; Pyrazinamide; Tuberculosis, Pulmonary	2018
Improving treatment outcome assessment in a mouse tuberculosis model. Scientific reports, 2018, 04-09, Volume: 8, Issue:1 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis	2018
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis]. Revista de neurologia, 2018, Apr-16, Volume: 66, Issue:8 Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resistance, Microbial; Drug Substitution; Ethambutol; Female; Host-Pathogen Interactions; Humans; Isoniazid; Magnetic Resonance Imaging; Meningitis, Viral; Moxifloxacin; Mycobacterium tuberculosis; Neuroimaging; Optic Chiasm; Paresis; Prednisone; Pyrazinamide; Rifampin; Thalamus; Tuberculoma; Tuberculosis, Meningeal; Vision Disorders	2018
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:12 Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant	2018
Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Humans; Liver; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Time Factors; Tuberculosis	2018
Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International journal of pharmaceutics, 2019, Oct-30, Volume: 570 Topics: A549 Cells; Administration, Inhalation; Aerosols; Antitubercular Agents; Cell Line; Cell Line, Tumor; Chemistry, Pharmaceutical; Diarylquinolines; Drug Compounding; Dry Powder Inhalers; Excipients; Humans; Moxifloxacin; Particle Size; Powders; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. The Journal of antimicrobial chemotherapy, 2020, 02-01, Volume: 75, Issue:2 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis	2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2021, Volume: 19, Issue:4 Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; Transplant Recipients; Treatment Outcome; Tuberculosis	2021
Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review. The American journal of tropical medicine and hygiene, 2021, 03-15, Volume: 104, Issue:5 Topics: Adult; Amikacin; Antitubercular Agents; Clofazimine; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Lost to Follow-Up; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pakistan; Pyrazinamide; Retrospective Studies; Survival Analysis; Treatment Failure; Tuberculosis, Multidrug-Resistant	2021
The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG. International journal of molecular sciences, 2021, Mar-13, Volume: 22, Issue:6 Topics: Amikacin; Antitubercular Agents; Bacterial Load; Cell Survival; Clofazimine; Cycloserine; Deferoxamine; Diarylquinolines; Drug Resistance, Bacterial; Drug Synergism; Gene Expression; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Iron; Iron Chelating Agents; Linezolid; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Primary Cell Culture; Pyrazinamide	2021
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR. Morbidity and mortality weekly report, 2022, Feb-25, Volume: 71, Issue:8 Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States	2022
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis	2022
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 08-01, Volume: 26, Issue:8 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pregnanes; Pyrazinamide; Rifampin; South Africa; Tuberculosis	2022
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis. Scientific reports, 2022, 10-22, Volume: 12, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization	2022
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability. mBio, 2023, 04-25, Volume: 14, Issue:2 Topics: Animals; Antitubercular Agents; Biological Availability; Dysbiosis; Humans; Isoniazid; Mice; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2023
Protein binding investigation of first-line and second-line antituberculosis drugs. International journal of antimicrobial agents, 2023, Volume: 62, Issue:6 Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis	2023
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. PloS one, 2023, Volume: 18, Issue:10 Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil	2023